296 related articles for article (PubMed ID: 27542119)
41. Synthesis and structure activity relationship of 1, 3-benzo-thiazine-2-thiones as selective HDAC8 inhibitors.
Wolff B; Jänsch N; Sugiarto WO; Frühschulz S; Lang M; Altintas R; Oehme I; Meyer-Almes FJ
Eur J Med Chem; 2019 Dec; 184():111756. PubMed ID: 31630054
[TBL] [Abstract][Full Text] [Related]
42. Structural insights of SmKDAC8 inhibitors: Targeting Schistosoma epigenetics through a combined structure-based 3D QSAR, in vitro and synthesis strategy.
Ballante F; Reddy DR; Zhou NJ; Marshall GR
Bioorg Med Chem; 2017 Apr; 25(7):2105-2132. PubMed ID: 28259528
[TBL] [Abstract][Full Text] [Related]
43. Structure-activity relationships of HDAC8 inhibitors: Non-hydroxamates as anticancer agents.
Amin SA; Adhikari N; Jha T
Pharmacol Res; 2018 May; 131():128-142. PubMed ID: 29514055
[TBL] [Abstract][Full Text] [Related]
44. Enhancing the Sensitivity of Pharmacophore-Based Virtual Screening by Incorporating Customized ZBG Features: A Case Study Using Histone Deacetylase 8.
Hou X; Du J; Liu R; Zhou Y; Li M; Xu W; Fang H
J Chem Inf Model; 2015 Apr; 55(4):861-71. PubMed ID: 25757142
[TBL] [Abstract][Full Text] [Related]
45. Potent and Selective Non-hydroxamate Histone Deacetylase 8 Inhibitors.
Kleinschek A; Meyners C; Digiorgio E; Brancolini C; Meyer-Almes FJ
ChemMedChem; 2016 Dec; 11(23):2598-2606. PubMed ID: 27860422
[TBL] [Abstract][Full Text] [Related]
46. Identification of a Histone Deacetylase 8 Inhibitor through Drug Screenings Based on Machine Learning.
Nurani A; Yamashita Y; Taki Y; Takada Y; Itoh Y; Suzuki T
Chem Pharm Bull (Tokyo); 2024; 72(2):173-178. PubMed ID: 38296560
[TBL] [Abstract][Full Text] [Related]
47. Synthesis and biological evaluation of ortho-aryl N-hydroxycinnamides as potent histone deacetylase (HDAC) 8 isoform-selective inhibitors.
Huang WJ; Wang YC; Chao SW; Yang CY; Chen LC; Lin MH; Hou WC; Chen MY; Lee TL; Yang P; Chang CI
ChemMedChem; 2012 Oct; 7(10):1815-24. PubMed ID: 22907916
[TBL] [Abstract][Full Text] [Related]
48. Fragment-Based Drug Design of Selective HDAC6 Inhibitors.
Ruzic D; Djokovic N; Nikolic K
Methods Mol Biol; 2021; 2266():155-170. PubMed ID: 33759126
[TBL] [Abstract][Full Text] [Related]
49. In-silico design of novel potential HDAC inhibitors from indazole derivatives targeting breast cancer through QSAR, molecular docking and pharmacokinetics studies.
Pandiyan S; Wang L
Comput Biol Chem; 2024 Jun; 110():108035. PubMed ID: 38460437
[TBL] [Abstract][Full Text] [Related]
50. Exploring the binding mechanism of HDAC8 selective inhibitors: Lessons from the modification of Cap group.
Zhang M; Ying JB; Wang SS; He D; Zhu H; Zhang C; Tang L; Lin R; Zhang Y
J Cell Biochem; 2020 Jun; 121(5-6):3162-3172. PubMed ID: 31907955
[TBL] [Abstract][Full Text] [Related]
51. Ligand-based virtual screening and in silico design of new antimalarial compounds using nonstochastic and stochastic total and atom-type quadratic maps.
Marrero-Ponce Y; Iyarreta-Veitía M; Montero-Torres A; Romero-Zaldivar C; Brandt CA; Avila PE; Kirchgatter K; Machado Y
J Chem Inf Model; 2005; 45(4):1082-100. PubMed ID: 16045304
[TBL] [Abstract][Full Text] [Related]
52. QSAR classification-based virtual screening followed by molecular docking studies for identification of potential inhibitors of 5-lipoxygenase.
Shameera Ahamed TK; Rajan VK; Sabira K; Muraleedharan K
Comput Biol Chem; 2018 Dec; 77():154-166. PubMed ID: 30321850
[TBL] [Abstract][Full Text] [Related]
53. Synthesis, Biological Evaluation, and Computer-Aided Drug Designing of New Derivatives of Hyperactive Suberoylanilide Hydroxamic Acid Histone Deacetylase Inhibitors.
Zhang S; Huang W; Li X; Yang Z; Feng B
Chem Biol Drug Des; 2015 Oct; 86(4):795-804. PubMed ID: 25763653
[TBL] [Abstract][Full Text] [Related]
54. Discovery of the first histone deacetylase 6/8 dual inhibitors.
Olson DE; Wagner FF; Kaya T; Gale JP; Aidoud N; Davoine EL; Lazzaro F; Weïwer M; Zhang YL; Holson EB
J Med Chem; 2013 Jun; 56(11):4816-20. PubMed ID: 23672185
[TBL] [Abstract][Full Text] [Related]
55. Matairesinol, an active constituent of HC9 polyherbal formulation, exhibits HDAC8 inhibitory and anticancer activity.
Mahajan M; Suryavanshi S; Bhowmick S; Alasmary FA; Almutairi TM; Islam MA; Kaul-Ghanekar R
Biophys Chem; 2021 Jun; 273():106588. PubMed ID: 33848944
[TBL] [Abstract][Full Text] [Related]
56. Pharmacophore Based 3D-QSAR, Virtual Screening and Docking Studies on Novel Series of HDAC Inhibitors with Thiophen Linker as Anticancer Agents.
Patel P; Singh A; Patel VK; Jain DK; Veerasamy R; Rajak H
Comb Chem High Throughput Screen; 2016; 19(9):735-751. PubMed ID: 27487787
[TBL] [Abstract][Full Text] [Related]
57. Design, synthesis and biological evaluation of tyrosine-based hydroxamic acid analogs as novel histone deacetylases (HDACs) inhibitors.
Zhang Y; Feng J; Liu C; Fang H; Xu W
Bioorg Med Chem; 2011 Aug; 19(15):4437-44. PubMed ID: 21733698
[TBL] [Abstract][Full Text] [Related]
58. Novel HDAC8 inhibitors: A multi-computational approach.
Manal M; Manish K; Sanal D; Selvaraj A; Devadasan V; Chandrasekar MJN
SAR QSAR Environ Res; 2017 Sep; 28(9):707-733. PubMed ID: 28965432
[TBL] [Abstract][Full Text] [Related]
59. Fragment based G-QSAR and molecular dynamics based mechanistic simulations into hydroxamic-based HDAC inhibitors against spinocerebellar ataxia.
Sinha S; Tyagi C; Goyal S; Jamal S; Somvanshi P; Grover A
J Biomol Struct Dyn; 2016 Oct; 34(10):2281-95. PubMed ID: 26510381
[TBL] [Abstract][Full Text] [Related]
60. Discovery of novel hit compounds as potential HDAC1 inhibitors: The case of ligand- and structure-based virtual screening.
Sirous H; Campiani G; Calderone V; Brogi S
Comput Biol Med; 2021 Oct; 137():104808. PubMed ID: 34478925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
